secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001213900-25-028366
Event type: debt
Sentiment:  positive
Materiality: 0.78
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake secures up to $500M non-dilutive loan from Hercules Capital; $75M drawn at close
--------------------------------------------------------------------------------

- Up to $500M non-dilutive term loan facility from Hercules Capital; $75M funded at close on March 31, 2025.
- Additional tranches up to $125M upon VELA Phase 3 HS success; further tranches for PsA and BLA acceptance.
- Facility matures April 1, 2030; interest rate prime+1.45% (floor 8.45%), 0.25% reduction on FDA BLA acceptance.
- Company had $448M cash (from 10-K); combined facility expected to fund sonelokimab launch in 2027.
- Capital Markets Update April 29, 2025: VELA baseline characteristics, primary endpoint readout timing, and Phase 2 LEDA interim data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390025028366/0001213900-25-028366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390025028366/ea0236970-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-028366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer